Article Sidebar

PDF
Date Published: 31/07/2022
Abstract Views: 141
Views PDF: 102
DOI: https://doi.org/10.51298/vmj.v516i2.3077
Issue
Vol. 516 No. 2 (2022)
Section
Các bài báo
How to Cite
Hùng Kiên, Đỗ ., & Văn Tài, N. . (2022). THE SURVIVAL OUTCOME OF CHEMOTHERAPY OF TRIPLET REGIMEN CAP IN METASTATIC SALIVARY GLAND CARCINOMA. Vietnam Medical Journal, 516(2). https://doi.org/10.51298/vmj.v516i2.3077

THE SURVIVAL OUTCOME OF CHEMOTHERAPY OF TRIPLET REGIMEN CAP IN METASTATIC SALIVARY GLAND CARCINOMA

Đỗ Hùng Kiên1,, Nguyễn Văn Tài1
1 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objective: Evaluating the survival outcome of chemotherapy of triplet regimen CAP in metastatic salivary gland carcinoma at National Cancer Hospital from 2015 to 2021. Patients and method: Retrospective analysis of 21 patients with metastatic salivary gland carcinoma were diagnosed and treated with chemotherapy of CAP regimen at National Cancer Hospital from 2015 to 2021. Results: The average age was 50.6±5.5, male/female ratio was 1.6/1. Mean recurrent time was 22+6.3 months. The pathology of adenoid cystic tumor was observed in 76%. Primary carcinoma, 42.9% patients had tumor of parotid gland origin and 33.3% submaxillary gland origin. Oligometastasis, accounted for 57.1% and lung metastasis was dominated with 76.2%, then mediastinal nodes and bone metastasis. Average free-progression survival was 7.3±2.1 months. 1-year and 2-year free-progression survival rates were 51.9% and 39.0%, respectively. Average overall survival was 17.5±3.1 months. 1-year and 2-year overall survival rates were 46.8% and 33.4%, respectively. Conclusion: Chemotherapy of triplet regimen CAP showed good survival outcome in patients with metastatic salivary gland carcinoma, average overall survival was 17.5±3.1 month

Article Details

Keywords

Metastatic salivary gland cancer, CAP regimen, National Cancer Hospital

References

1. Dreyfuss AI, Clark JR, Fallon BG (1987). Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987; 60(12): 2869.
2. Kaplan MJ, Johns ME, Cantrell RW (1986). Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95(2):165.
3. Licitra L, Cavina R, Grandi C (1996). Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7(6):640.
4. Tsukuda M, Kokatsu T, Ito K, Mochimatsu I (1993). Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol. 1993;119(12):756.
5. Dimery IW, Legha SS, Shirinian M (1990). Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol. 1990;8(6):1056.
6. Venook AP, Tseng A Jr, Meyers FJ (1987). Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987;5(6):951.
7. Airoldi M, Pedani F, Brando V (1989). Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori. 1989;75(3):252.